Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
JA Kagihara, M Andress… - Expert review of precision …, 2020 - Taylor & Francis
Introduction: Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
[PDF][PDF] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
JA Kagihara, M Andress, JR Diamond - academia.edu
Introduction—Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
JA Kagihara, M Andress… - Expert review of …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15-20%. The standard of care for …
and triple-negative breast cancer (TNBC) accounts for 15-20%. The standard of care for …
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
JA Kagihara, M Andress, JR Diamond - Expert Review of Precision …, 2020 - europepmc.org
Breast cancer is the most common malignancy in women in the United States and triple-
negative breast cancer (TNBC) accounts for 15-20%. The standard of care for metastatic …
negative breast cancer (TNBC) accounts for 15-20%. The standard of care for metastatic …
[HTML][HTML] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
JA Kagihara, M Andress… - Expert review of precision …, 2020 - ncbi.nlm.nih.gov
Introduction—Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
JA Kagihara, M Andress, JR Diamond - Expert Review of Precision …, 2020 - europepmc.org
Introduction—Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …